Richard Stewart
2021
In 2021, Richard Stewart earned a total compensation of $1.3M as Executive Chairman at OncoGenex Pharmaceuticals, a 29% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $260,000 |
---|---|
Option Awards | $540,235 |
Salary | $400,000 |
Stock Awards | $130,900 |
Total | $1,331,135 |
Stewart received $540.2K in option awards, accounting for 41% of the total pay in 2021.
Stewart also received $260K in non-equity incentive plan, $400K in salary and $130.9K in stock awards.
Rankings
In 2021, Richard Stewart's compensation ranked 7,733rd out of 12,415 executives tracked by ExecPay. In other words, Stewart earned more than 37.7% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 7,733 out of 12,415 | 38th |
Division Manufacturing | 3,411 out of 5,508 | 38th |
Major group Chemicals And Allied Products | 1,513 out of 2,378 | 36th |
Industry group Drugs | 1,347 out of 2,099 | 36th |
Industry In Vitro and In Vivo Diagnostic Substances | 29 out of 61 | 53rd |
Source: SEC filing on April 21, 2022.
Stewart's colleagues
We found two more compensation records of executives who worked with Richard Stewart at OncoGenex Pharmaceuticals in 2021.
News
OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
April 28, 2023
OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
April 21, 2022
OncoGenex Pharmaceuticals CEO Richard Stewart's 2020 pay jumps 30% to $1M
March 30, 2021
OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
April 2, 2020
OncoGenex Pharmaceuticals CEO Richard Stewart's 2018 pay jumps 423% to $1.1M
March 28, 2019